Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models
Open Access
- 24 November 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 14 (12), 1737-1744
- https://doi.org/10.1002/lt.21621
Abstract
This study investigated the effects of dual endothelin (ET) receptor blockade in rat models of liver ischemia and reperfusion injury (IRI). Three models of IRI were used: (1) in vivo total hepatic warm ischemia with portal shunting for 60 minutes with control (saline) and treatment groups (15 mg/kg tezosentan intravenously prior to reperfusion), (2) ex vivo hepatic perfusion after 24 hours of cold storage in University of Wisconsin solution with control and treatment groups (10 mg/kg tezosentan in the perfusate), and (3) syngeneic liver transplantation (LT) after 24 hours of cold storage in University of Wisconsin solution with control and treatment groups (10 mg/kg tezosentan intravenously prior to reperfusion). Tezosentan treatment significantly improved serum transaminase and histology after IRI in all 3 models. This correlated with reduced vascular resistance, improved bile production, and an improved oxygen extraction ratio. Treatment led to a reduction in neutrophil infiltration and interleukin‐1 beta and macrophage inflammatory protein 2 production. A reduction in endothelial cell injury as measured by purine nucleoside phosphorylase was seen. Survival after LT was significantly increased with tezosentan treatment (90% versus 50%). In conclusion, this is the first investigation to examine dual receptor ET blockade in 3 models of hepatic IRI and the first to use the parenterally administered agent tezosentan. The results demonstrate that in both warm and cold IRI tezosentan administration improves sinusoidal hemodynamics and is associated with improved tissue oxygenation and reduced endothelial cell damage. In addition, reduced tissue inflammation, injury, and leukocyte chemotactic signaling were seen. These results provide compelling data for the further investigation of the use of tezosentan in hepatic IRI. Liver Transpl 14:1737–1744, 2008. © 2008 AASLD.Keywords
Funding Information
- Dumont Research Fund
- JoAnn Barr Foundation
This publication has 37 references indexed in Scilit:
- Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bileBritish Journal of Clinical Pharmacology, 2003
- Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injuryJournal of Gastrointestinal Surgery, 2001
- Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liverHepatology, 2000
- Endothelin Receptor Blockade as a Therapeutic Strategy in Ameliorating Postischemic Damage to the Liver MicrocirculationJournal of Cardiovascular Pharmacology, 2000
- Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injuryJCI Insight, 1999
- Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and kupffer cellsHepatology, 1998
- NEUTROPHIL INFILTRATION AS AN IMPORTANT FACTOR IN LIVER ISCHEMIA AND REPERFUSION INJURYTransplantation, 1993
- Hepatic tissue oxygenation as a predictive indicator of ischemia-reperfusion liver injuryHepatology, 1992
- Hypoxia induces endothelin gene expression and secretion in cultured human endothelium.JCI Insight, 1991
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990